Tschan, Viviane J.
Borgna, Francesca
Busslinger, Sarah D.
Stirn, Martina
Rodriguez, Josep M. Monné
Bernhardt, Peter
Schibli, Roger
Müller, Cristina
Funding for this research was provided by:
Personal Health and Related Technologies (PHRT 301)
Horizon 2020 (N° 701647)
Krebsforschung Schweiz (N° KFS-4678-02-2019-R)
Stiftelsen Konung Gustaf V:s Jubileumsfond
Swedisch Cancer Society
Swedish Research Council
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_188978)
PSI - Paul Scherrer Institute
Article History
Received: 6 November 2021
Accepted: 8 May 2022
First Online: 30 May 2022
Declarations
:
: This study was performed in agreement with the national law and PSI-internal guidelines of radiation safety protection. In vivo experiments were approved by the local veterinarian department and ethics committee and conducted in accordance with the Swiss law of animal protection.
: The authors declare that the following competing financial interest(s): Patent applications on PSMA ligands with albumin-binding entities have been filed by ITM Medical Isotopes GmbH, Germany.